May 20, 2019, Coralville, IA – Emmyon is pleased to announce that seven leading scientists have joined our Scientific Advisory Board, bringing deep expertise and capabilities in drug development, clinical nutrition, skeletal muscle biology, metabolism, obesity, diabetes, aging and translational research. Our new SAB members are Drs. Sue Bodine, Daryl Granner, Peter Snyder, Blake Rasmussen, Bret Goodpaster, Teresa Zimmers, and Andrew Judge. Please see our Scientific Advisory Board page for further information.
Emmyon receives a new Australian patent for ursolic acid and a new European patent for tomatidine
January 11, 2019, Coralville, IA – Emmyon is pleased to announce that the Australian Patent Office has issued a new patent for the use of ursolic acid to increase muscle mass or reduce muscle atrophy, and the European Patent Office has issued a new patent for methods and compositions for treating muscle atrophy, increasing muscle mass and/or enhancing muscle formation using tomatidine. These new patents, which are exclusively licensed to Emmyon from the University of Iowa Research Foundation, significantly expand Emmyon’s IP coverage around ursolic acid and tomatidine. The patents’ lead inventor is Emmyon’s President, Chris Adams, MD, PhD.
Emmyon appoints John Talley, PhD as Vice President – Chemistry
December 16, 2018, Coralville, IA. – Emmyon is pleased to announce that Dr. John Talley has become the company’s Vice President of Chemistry. John has served as senior scientific advisor at Emmyon and led the company’s chemistry program since 2012. He is one of the world’s most accomplished medicinal chemists and an inventor on more than 200 issued U.S. patents. His inventions include the COX-2 specific inhibitors Celebrex®, Bextra®, Dynastat®, Deramaxx® and Trocoxil® and the hydroxyethyl sulfonamide class of inhibitors for the treatment of HIV/AIDS, marketed under the brand names of Agenerase® , Telzir® , and Prezista®. The medicines invented by Dr. Talley have improved the health of millions of patients and generated over $40 billion in sales to date. He received the prestigious PhRMA Discoverers Award in 2002 for the discovery of Celebrex®. For the past four years (2015-2018), Dr. Talley has been named to The Medicine Maker Power List, which recognizes the world’s most influential people in drug discovery and development.
Emmyon receives a third US patent for ursolic acid
November 27, 2018, Coralville, IA. – Emmyon is pleased to announce that the United States Patent and Trademark Office has today issued a new patent for the use of ursolic acid to enhance muscle formation, increase muscle mass, or reduce muscle atrophy. This new patent, which has been exclusively licensed to Emmyon from the University of Iowa Research Foundation, complements and greatly strengthens Emmyon’s IP coverage of ursolic acid in the United States. The patent’s lead inventor is Emmyon’s President, Chris Adams, MD, PhD.
Emmyon receives Phase II SBIR award from the National Institutes of Health
September 30, 2018, Coralville, IA – Emmyon is pleased to announce that it has received a new Phase II Small Business Innovation Research (SBIR) award from the National Institute on Aging (NIA) at the US National Institutes of Health (NIH). The funding will support further development of novel pharmaceutical compounds for skeletal muscle atrophy.
Skeletal muscle atrophy, also known as muscle wasting, is a widespread and serious condition that affects tens of millions of people in the US alone. Causes of muscle atrophy include aging, malnutrition, muscle disuse, critical illness, certain medications, and a broad range of chronic illnesses including cancer, heart failure, COPD, diabetes, renal failure, cirrhosis, rheumatoid arthritis, and HIV/AIDS. Effects of muscle atrophy include weakness, impaired activity, falls, prolonged hospitalization, delayed rehabilitation, loss of independent living, and increased mortality. Unfortunately, right now, we do not have any medicines to help prevent or treat muscle atrophy. Our research seeks to address this problem. We’re very grateful to the NIA and the NIH for their continued support of these efforts.
NIH selects Emmyon for the Innovation Zone at the 2017 BIO International Convention
April 20, 2017, Coralville, IA. – We are pleased to announce that the National Institutes of Health (NIH) has selected Emmyon to exhibit and showcase its technology at the 2017 BIO International Convention, which will be held in San Diego, CA from June 19-22, 2017. Emmyon will be located within the NIH’s Innovation Zone. We’re honored and excited to participate as an NIH-sponsored company at the world’s largest biotechnology conference and exhibition.